Phase II study of amrubicin (SM-5887), a synthetic 9-aminoanthracycline, as first line treatment in patients with metastatic or unresectable soft tissue sarcoma: durable response in myxoid liposarcoma with TLS-CHOP translocation.
about
Phase II study of amrubicin (SM-5887), a synthetic 9-aminoanthracycline, as first line treatment in patients with metastatic or unresectable soft tissue sarcoma: durable response in myxoid liposarcoma with TLS-CHOP translocation.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Phase II study of amrubicin (S ...... a with TLS-CHOP translocation.
@en
Phase II study of amrubicin (S ...... a with TLS-CHOP translocation.
@nl
type
label
Phase II study of amrubicin (S ...... a with TLS-CHOP translocation.
@en
Phase II study of amrubicin (S ...... a with TLS-CHOP translocation.
@nl
prefLabel
Phase II study of amrubicin (S ...... a with TLS-CHOP translocation.
@en
Phase II study of amrubicin (S ...... a with TLS-CHOP translocation.
@nl
P2093
P2860
P1476
Phase II study of amrubicin (S ...... a with TLS-CHOP translocation.
@en
P2093
Debbie Pitt
Jennifer Wright
Ken Boucher
Launce Gouw
Sant Chawla
Sunil Sharma
P2860
P2888
P304
P356
10.1007/S10637-016-0333-Z
P50
P577
2016-02-20T00:00:00Z